Industry Insights: Healthcare 31 January
We have summarised three articles to help keep you informed of the latest developments in the industry. This week, our Industry Insights post looks at three important updates from the U.S. Food and Drug Administration (FDA). The FDA has investigated the risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T-cell […]
Industry Insights: Healthcare 18 December
We have summarised three articles to help keep you informed of the latest developments in the industry. This week our Industry Insights focus on a major breakthrough for severe asthma treatment, three-year follow-up data from the phase 2b randomised KEYNOTE-942-/mRNA-4157-P201 study, and a new clinical trial looking at stem cell-based treatment for blood glucose control […]
Industry Insights: Healthcare 28 November
We have summarised three articles to help keep you informed of the latest developments in the industry. This week our Industry Insights look at the U.S Food and Drug Administration (FDA) approval of Zepbound (tirzepatide) for chronic weight management, a World Health Organisation (WHO) statement on reported clusters of respiratory illness in children in northern […]
Industry Insights: Healthcare 6 November
This week our Industry Insights: Healthcare looks at the potential for Food and Drug Administration (FDA) approval of CRISPR for sickle cell anaemia, new lung cancer screening guidelines by the American Cancer Society, and FDA approval for Phathom’s Voquezna. A panel of external advisors to the FDA has found the safety data for Exagamglogene Autotemcel […]
Industry Insights: Healthcare 16 October
Industry Insights: Healthcare
Industry Insights: Healthcare 25 September
This week our industry insights look at news highlighting the importance of full disclosure in the promotion of medicines, EU recommendation for the approval of an antibody-drug for the treatment of NSCLC, and a popular oral decongestant that could be removed from the US market. Novartis has been found to have seriously breached the ABPI […]
Industry Insights: Healthcare 11 September
This week, our industry news insights looks at an announcement of a new phase III trial for non-small cell lung cancer, artificial intelligence (AI) for breast cancer detection, and dramatic increases in cancer rates for under-50s. Taiho Oncology and Cullian Oncology have announced the phase III trial of zipalertinib in EGFR exon 20 insertion mutation […]
Industry insights: Healthcare 28th of August
Here are three briefly summarised articles to help keep you informed of the latest developments in the industry. This week take a look at new US Government funding into vaccines and therapies for COVID and FDA clearance for new AI technology to help spot lung nodules. We also explore the impact of Keytruda (pembrolizumab) in […]
Industry Insights: Healthcare 14 August
Here are three briefly summarised articles to help keep you informed of the latest developments in the industry. This week our industry insights look at news highlighting how artificial intelligence (AI) could be used for cancers of unknown primary origin, further findings from a Novo Nordisk’s Wegovy trial, and a new novel oral treatment for […]
Industry insights: Healthcare 1st of August
Obesity and rheumatological conditions are an area of Elion’s expertise. This week our industry news insights look at the correlation between obesity and psoriasis, findings from a trial of a promising treatment for Alzheimer’s, and the initiation of Phase III study involving Merck’s Keytruda. It is well established that obesity is a risk factor for […]
Industry insights: Healthcare 3rd of July
Oncology, particularly lung and breast cancer, is an area of Elion’s expertise. This week we have found news highlighting the progress made in small cell lung cancer, identification of a new subtype of depression, and a promising trend in breast cancer survival rates. Small cell lung cancer (SCLC) accounts for 13-15% of all lung cancer […]
Industry insights: Healthcare 26th of June
Mental health is one of Elion’s areas of expertise. This week we’ve found industry news highlighting promising therapies for Alzheimer’s and schizophrenia, as well as a caution about commenting on social media. Independent advisors to the FDA have unanimously agreed that Leqembi, an Alzheimer’s drug being developed by Eisai-Biogen, benefits patients. Leqembi is an amyloid beta-directed […]
